Radiopharm Theranostics Statistics
Share Statistics
Radiopharm Theranostics has -
shares outstanding. The number of shares has increased by null%
in one year.
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 587 |
| FTD / Avg. Volume | 0.32% |
Short Selling Information
The latest short interest is 24.96K, so 0% of the outstanding
shares have been sold short.
| Short Interest | 24.96K |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.05 |
Valuation Ratios
| PE Ratio | 0 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Radiopharm Theranostics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.3,
with a Debt / Equity ratio of 0.
| Current Ratio | 1.3 |
| Quick Ratio | 1.3 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -56.96 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | undefined |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 96.36K |
| Effective Tax Rate | -0.2% |
Stock Price Statistics
The stock price has increased by null% in the
last 52 weeks. The beta is 0.8, so Radiopharm Theranostics's
price volatility has been higher than the market average.
| Beta | 0.8 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 4.6 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 49.86 |
| Average Volume (20 Days) | 182,561 |
Income Statement
In the last 12 months, Radiopharm Theranostics had revenue of 299.23K
and earned -47.95M
in profits. Earnings per share was 0.
| Revenue | 299.23K |
| Gross Profit | 299.23K |
| Operating Income | -36.62M |
| Net Income | -47.95M |
| EBITDA | -44.08M |
| EBIT | -47.21M |
| Earnings Per Share (EPS) | 0 |
Full Income StatementBalance Sheet
The company has 18.58M in cash and 0 in
debt, giving a net cash position of 18.58M.
| Cash & Cash Equivalents | 18.58M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -111.34M |
| Total Assets | n/a |
| Working Capital | n/a |
Full Balance SheetCash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | -22.98M |
| FCF Per Share | 0 |
Full Cash Flow StatementMargins
Gross margin is 100%, with operating and profit margins of -12238.44% and -16024.28%.
| Gross Margin | 100% |
| Operating Margin | -12238.44% |
| Pretax Margin | -15992.07% |
| Profit Margin | -16024.28% |
| EBITDA Margin | -14732.44% |
| EBIT Margin | -12238.44% |
| FCF Margin | -7678.4% |
